News

ASH12: New Proteasome Inhibitor Shines In All-Oral Myeloma Regimen


 

Experimental MLN9708 is the first oral proteasome inhibitor, and it has shown itself to be highly active in a phase I/II clinical trial that enrolled 65 patients with newly diagnosed multiple myeloma.

Investigators reported that 92% responded to an all-oral regimen combining MLN9708 with lenalidomide (Revlimid) and dexamethsone. This included 55% with at least a very good partial response and 23% in complete response. A phase III trial is planned

Patrice Wendling interviewed Dr. Shaji K. Kumar on findings he presented at the annual meeting of the American Society of Hematology.

Recommended Reading

Arrhythmia risk prompts 32-mg IV ondansetron withdrawal
MDedge Hematology and Oncology
Mammograms Dip in Wake of USPSTF Recommendations
MDedge Hematology and Oncology
PET/CT Pinpoints Physiological Evidence of Chemo Brain
MDedge Hematology and Oncology
Genetic Vulnerabilities Identified in Residual TNBC After Neoadjuvant Chemo
MDedge Hematology and Oncology
Late Leukemia Risk Rises after Breast Cancer Therapy
MDedge Hematology and Oncology
San Antonio Roundtable, Part 4: Everolimus in Clinical Practice, a New CDK Inhibitor
MDedge Hematology and Oncology
HEM-ONC CHAT: What Research Area is on Top of Your Agenda?
MDedge Hematology and Oncology
ASH12: Apixaban cuts risk of venous thromboembolism
MDedge Hematology and Oncology
HEM-ONC CHAT: Dr. James N. George, 'Keep At It'
MDedge Hematology and Oncology
Studies put kibosh on statins for breast cancer prevention
MDedge Hematology and Oncology